This week addressed AI accountability, CPHI award winners, NFC anticounterfeiting, first-in-class FDA approvals, and a shelved FDA voucher pilot lead this week’s roundup.
|Videos|June 30, 2022
ApiJect’s Strategy and Adaptation of BFS Technology
Author(s)Apiject
BFS technology allows for rapid scale-up with flexible production runs, a versatile supply chain, and versatile product development.
Any formulation is checked for compatibility in ApiJect’s container, where they look for a loss of potency and impurities compared to other containers that are used.
To meet the demand in the market, ApiJect is working with external supply chains for contract manufacturing.
Related to this article
Cole and Jaenisch explain why defending against AI poisoning in pharma manufacturing calls for a data steward role, immutable instruction ledgers, and automation.
Gloveless isolators don’t end interventions. Learn to assess intervention dependency in robotic aseptic filling and when glove ports are justified.
Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how the company’s product is worth the investment by protecting products and patients.
The FDA has shelved its National Priority Voucher pilot, leaving sponsors that built CMC and launch-readiness plans around 1- to 2-month reviews facing uncertain timelines.
Regulators will test pharma companies against their own internal AI policies. Jaenisch, Muraru, and Pandey explain how to build defensible, inspection-ready AI practices.
Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how its connected technology can enhance anticounterfeiting and how data are handled within the product.
Celtic Renewables won the CPHI Award for Sustainable Pharma Excellence for its green chemicals used in pharmaceutical manufacturing. Bettina Brierley, chief commercial officer, talks about the adoption, capacity, and pricing of biosolvents.
Trending on Pharmaceutical Technology
1
CPHI Pharma Award Winner: Drug Delivery, Devices, & Packaging
2
Manufacturing Intelligence: AI Poisoning Demands Pharma Data Stewards
3
Signs Point to FDA Shelving Priority Voucher Pilot, Stalling Fast-Track Drug Reviews
4
Investing in Protecting Pharma Products
5